Crossmark

Rationale for metronomic chemotherapy in phase III trials

Crossref DOI link: https://doi.org/10.1038/nrclinonc.2015.89

Published Online: 2015-05-12

Published Print: 2015-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kerbel, Robert S.

Grothey, Axel
License Information

Text and Data Mining valid from 2015-05-12
More Information

Article History

First Online: 12 May 2015

Competing interests

: R.S.K. receives consulting fees/honoraria from Angiocrine Biosciences, Boehringer–Ingelheim, Cerulean Pharma, Eli-Lilly, Merrimack, MolMed, and Triphase Accelerator. R.S.K. also has stock options from Angiocrine Biosciences. The Mayo Clinic Foundation received research funding and honoraria for consulting activities by A.G. from Bayer, Eisai, Eli-Lilly, Genentech, and Pfizer.